With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to t ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

For TTY users: Use your preferred relay service or dial 711 then 988. Eli Lilly’s Kisunla is one of two drugs on the market aimed at slowing the progression of Alzheimer’s disease. But the ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

November is Alzheimer's Awareness Month and 7 News met Grand Island couple Tom and Michele Drabik, who shared their ...

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with oedema/effusion (ARIA-E). Lilly announced ...

LONDON (AP) — Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment ...